Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Treatment for recurrent ovarian cancer depends first on how long it has been since the last platinum dose, then on the cancer’s histology, prior treatments, biomarker results, symptoms, overall health, and the patient’s goals. A recurrence more than six months after platinum-based induction is generally considered platinum-sensitive, so another platinum combination is usually considered. Recurrence within six months is generally platinum-resistant; disease that progresses during induction is platinum-refractory, and treatment usually shifts away from platinum. These categories guide the discussion, but a gynecologic oncologist must tailor the plan to the individual.
What does platinum-sensitive, platinum-resistant, or platinum-refractory mean?
The National Cancer Institute (NCI) describes these categories by the timing of recurrence or progression in relation to platinum-based induction therapy:
- Platinum-sensitive: The cancer recurs more than six months after induction therapy ends. The NCI says retreatment with platinum or a platinum-containing combination should be considered.
- Platinum-resistant: The cancer recurs within six months after induction therapy ends. Platinum is generally not useful in the treatment plan.
- Platinum-refractory: The cancer progresses during induction therapy.
The six-month interval is a treatment-planning category, not a complete description of the cancer or a guarantee of how it will respond. The prior response, treatments received, and current disease also matter.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →What treatments are used for platinum-sensitive recurrence?
The American Society of Clinical Oncology (ASCO) 2026.1.0 living guideline recommends offering a platinum-based combination for recurrent platinum-sensitive epithelial ovarian cancer. Its recommendations cover recurrent high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, and primary peritoneal cancer.
#1 Best Overall
| Regimen | Role in the ASCO guideline |
|---|---|
| Carboplatin plus pegylated liposomal doxorubicin (PLD) | Recommended platinum combination |
| Carboplatin plus paclitaxel | Recommended platinum combination |
| Carboplatin plus gemcitabine | Recommended platinum combination |
ASCO does not establish one of these combinations as universally superior. The choice depends on prior treatment and response, expected side effects, contraindications, and the patient’s preferences. Bevacizumab may be added to a platinum doublet. For a patient who responds to recurrent-disease platinum therapy given with bevacizumab, ASCO says maintenance bevacizumab is an option.
Is PARP-inhibitor maintenance automatic?
No. ASCO notes that the role of PARP inhibitors in second-line or later maintenance has changed as frontline use, longer-term efficacy and safety evidence, and regulatory status have evolved. The guideline advises highly selective use rather than treating maintenance as automatic or universally available. Current local guidance and product labeling should be checked for an individual treatment decision.
Rank #2
What if the cancer comes back within six months, or progresses during platinum treatment?
For platinum-resistant or platinum-refractory recurrence, ASCO recommends considering treatments other than another platinum regimen. Options in its living guideline include PLD, paclitaxel, bevacizumab combined with chemotherapy, and—conditionally—relacorilant with nab-paclitaxel. Gemcitabine alone is a conditional alternative. The specific choice depends on the cancer and the patient’s treatment history and circumstances.
When is mirvetuximab soravtansine an option?
For high-grade disease with validated folate receptor alpha (FRα) expression, ASCO strongly recommends mirvetuximab soravtansine. The guideline defines FRα positivity by immunohistochemistry as at least 75% of cells staining at intensity 2+ or 3+.
Rank #3
In the United States, the Food and Drug Administration (FDA) approved mirvetuximab soravtansine-gynx (Elahere) on March 22, 2024, for adults with FRα-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens. Selection must use an FDA-approved test; the indication and test requirement are US-specific.
In MIRASOL, a randomized study of 453 patients in the specified population, median overall survival was 16.5 months with mirvetuximab versus 12.7 months with investigator-choice chemotherapy. Median progression-free survival was 5.6 versus 4.0 months, and objective response was 42% versus 16%. These are results for the study population, not a prediction of an individual patient’s outcome. The FDA prescribing-information warning includes ocular toxicity; listed risks also include pneumonitis and peripheral neuropathy.
Can surgery help with recurrent ovarian cancer?
Secondary cytoreductive surgery is not a routine next step for every recurrence. ASCO finds insufficient evidence to recommend secondary cytoreduction or hyperthermic intraperitoneal chemotherapy (HIPEC) routinely. For platinum-sensitive recurrence, clinicians may discuss secondary cytoreduction when complete gross resection appears highly achievable. Suitability and the likelihood of removing all visible disease are central to that discussion; surgical trial eligibility and complete-resection rates have varied, as the NCI notes.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsHow do prior treatment, testing, and personal goals shape the plan?
Before choosing among options, the patient and care team need to consider the whole treatment history and current situation, not just the interval since platinum. Relevant factors include:
Best Value
- Histology and grade, and whether the disease fits the population covered by the guideline.
- Prior response, exposure, or intolerance to platinum, taxanes, bevacizumab, and PARP inhibitors.
- FRα test results and whether the assay is valid for considering mirvetuximab.
- Symptoms, expected disease control, likely adverse effects, overall health, and treatment goals.
- Whether surgery is appropriate and whether complete gross resection is highly achievable.
- Whether a clinical trial is available and suitable.
Clinical trials are reasonable to discuss, particularly when standard options are limited. Treatment approvals and availability vary by country and can change, so decisions should be checked against current local guidance and labeling.
What follow-up is needed after treatment?
ASCO supports individualized follow-up and survivorship care rather than one universal monitoring schedule. Depending on the person’s circumstances, monitoring may include physical examinations, biochemical testing, or imaging. The appropriate approach is a case-by-case decision with the treating team.
How common is recurrence?
The NCI’s online summary, accessed October 3, 2026, reports that approximately 80% of patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer relapse after first-line platinum- and taxane-based chemotherapy. That figure describes the populations named in the summary; it does not determine an individual’s prognosis or treatment response.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
